Study Shows Businesses Selling Unapproved Stem Cell Treatments Have Turned to Long COVID

JAMA. 2023 Dec 26;330(24):2326-2327. doi: 10.1001/jama.2023.23897.
No abstract available

Plain language summary

This Medical News article discusses a new study that identified how business have pivoted marketing of unapproved stem cell and exosome products from COVID-19 to long COVID.

MeSH terms

  • COVID-19 / economics
  • COVID-19 / therapy
  • Commerce
  • Drug Approval*
  • Humans
  • Marketing
  • Post-Acute COVID-19 Syndrome* / economics
  • Post-Acute COVID-19 Syndrome* / therapy
  • Stem Cell Transplantation* / economics
  • Stem Cells